Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
The European Journal of Health Economics
Erschienen in: The European Journal of Health Economics 1/2014

01.05.2014 | Original Paper

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

verfasst von: László Gulácsi, Fanni Rencz, Márta Péntek, Valentin Brodszky, Ruth Lopert, Noémi V. Hevér, Petra Baji

Erschienen in: The European Journal of Health Economics | Sonderheft 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Several Central and Eastern European (CEE) countries require cost-utility analyses (CUAs) to support reimbursement formulary listing. However, CUAs informed by local evidence are often unavailable, and the cost-effectiveness of the several currently reimbursed biologicals is unclear.

Aim

To estimate the cost-effectiveness as multiples of per capita GDP/quality adjusted life years (QALY) of four biologicals (infliximab, etanercept, adalimumab, golimumab) currently reimbursed in six CEE countries in six inflammatory rheumatoid and bowel disease conditions.

Methods

Systematic literature review of published cost-utility analyses in the selected conditions, using the United Kingdom (UK) as reference country and with study selection criteria set to optimize the transfer of results to the CEEs. Prices in each CEE country were pro-rated against UK prices using purchasing power parity (PPP)-adjusted per capita GDP, and local GDP per capita/QALY ratios estimated.

Results

Central and Eastern European countries list prices were 144–333 % higher than pro rata prices. Out of 85 CUAs identified by previous systematic literature reviews, 15 were selected as a convenience sample for estimating the cost-effectiveness of biologicals in the CEE countries in terms of per capita GDP/QALY. Per capita GDP/QALY values varied from 0.42 to 6.4 across countries and conditions (Bulgaria: 0.97–6.38; Czech Republic: 0.42–2.76; Hungary: 0.54–3.54; Poland: 0.59–3.90; Romania: 0.77–5.07; Slovakia: 0.55–3.61).

Conclusion

While results must be interpreted with caution, calculating pro rata (cost-effective) prices and per capita GDP/QALY ratios based on CUAs can aid reimbursement decision-making in the absence of analyses using local data.
Fußnoten
1
Source: personal communication.
 
Literatur
1.
Gulácsi, L., Rotar, A.M., Niewada, M., Löblová, O., Rencz F., Petrova, G., Boncz, I., Klazinga, N.S.: Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur. J. Health Econ. This Supplement (2014). doi:10.​1007/​s10198-014-0590-8
2.
Lopert, R., Lang, D.L., Hill, S.R., Henry, D.A.: Differential pricing of drugs: a role for cost-effectiveness analysis? Lancet 359, 2105–2107 (2002)PubMedCrossRef
3.
Lopert, R., Ruiz, F., Chalkidou, K.: Applying rapid ‘de-facto’ HTA in resource-limited settings: experience from Romania. Health Policy 112(3), 202–208 (2013)PubMedCrossRef
4.
Drummond, M., Barbieri, M., Cook, J., Glick, H.A., Lis, J., Malik, F., Reed, S.D., Rutten, F., Sculpher, M., Severens, J.: Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 12(4), 409–418 (2009)PubMedCrossRef
5.
6.
7.
8.
9.
10.
11.
Péntek, M., Kobelt, G., Czirják, L., Szekanecz, Z., Poór, G., Rojkovich, B., Polgár, A., Genti, G., Kiss, C.G., Brodszky, V., Májer, I., Gulácsi, L.: Costs of rheumatoid arthritis in Hungary. J. Rheumatol. 34(6), 1437 (2007)PubMed
12.
Brodszky, V., Bálint, P., Géher, P., Hodinka, L., Horváth, G., Koó, É., Péntek, M., Polgár, A., Seszták, M., Szántó, S., Ujfalussy, I., Gulácsi, L.: Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol. Int. 30(2), 199–205 (2009)PubMedCrossRef
13.
Brodszky, V., Orlewska, E., Péntek, M., Kárpáti, K., Skoupá, J., Gulácsi, L.: Challenges in economic evaluation of new drugs: experience with rituximab in Hungary. Med. Sci. Monit. 16(1), SR1–SR5 (2010)PubMed
14.
Brennan, A., Bansback, N., Reynolds, A., Conway, P.: Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford). 43(1), 62–72 (2004)
15.
Barbieri, M., Wong, J.B., Drummond, M.: The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics. 23(6), 607-18 (2005)
16.
Chen, Y.F., Jobanputra, P., Barton, P., Jowett, S., Bryan, S., Clark, W., Fry-Smith, A., Burls A.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 10(42), iii–iv, xi–xiii, 1–229 (2006)
17.
Kobelt, G., Sobocki, P., Sieper, J., Braun, J.: Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. Int. J. Technol. Assess. Health Care 23, 368–375 (2007)PubMedCrossRef
18.
Ara, R.M., Reynolds, A.V., Conway, P.: The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology (Oxford) 46, 1338–1344 (2007)CrossRef
19.
Botteman, M.F., Hay, J.W., Luo, M.P., Curry, A.S., Wong, R.L., van Hout, B.A.: Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford) 46(8), 1320–1328 (2007)CrossRef
20.
Riemsma, R., Joore, M., Van Asselt, T., Armstrong, N., Misso, K., Manning, N., Tomini, F., Kleijnen, J.: Golimumab for the treatment of ankylosing spondylitis: a single technology appraisal. Kleijnen Systematic Reviews Ltd., York (2011)
21.
Bravo Vergel, Y., Hawkins, N.S., Claxton, K., Asseburg, C., Palmer, S., Woolacott, N., Bruce, I.N., Sculpher, M.J.: The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology 46, 1729–1735 (2007)PubMedCrossRef
22.
Bojke, L., Epstein, D., Craig, D., Rodgers, M., Woolacott, N., Yang, H., Sculpher, M.: Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology 50(Suppl 4), iv39–iv47 (2011)PubMedCrossRef
23.
Yang, H., Craig, D., Epstein, D., Bojke, L., Light, K., Bruce, I.N., Sculpher, M., Woolacott, N.: Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics 30(4), 257–270 (2012)PubMedCrossRef
24.
Lindsay, J., Punekar, Y.S., Morris, J., Chung-Faye, G.: Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohnʼs disease–modelling outcomes in active luminal and fistulizing disease in adults. Aliment. Pharmacol. Ther. 28, 76–87 (2008)PubMedCrossRef
25.
Bodger, K., Kikuchi, T., Hughes, D.: Cost-effectiveness of biological therapy for Crohnʼs disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment. Pharmacol. Ther. 30, 265–274 (2009)PubMedCrossRef
26.
Loftus Jr, E.V., Johnson, S.J., Yu, A.P., Wu, E.Q., Chao, J., Mulani, P.M.: Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohnʼs disease. Eur. J. Gastroenterol. Hepatol. 21, 1302–1309 (2009)PubMedCrossRef
27.
Hyde, C., Bryan, S., Juarez-Garcia, A., Andronis, L., Fry-Smith, A.: Evidence review group report commissioned by the NHS R&D HTA programme on behalf of NICE infliximab for ulcerative colitis. West Midlands Health Technology Assessment Collaboration, Department of Public Health and Epidemiology, University of Birmingham (2007)
28.
Sizto, S., Bansback, N., Feldman, S.R., Willian, M.K., Anis, A.H.: Economic evaluation of systemic therapies for moderate to severe psoriasis. Br. J. Dermatol. 160(6), 1264–1272 (2009)PubMedCrossRef
29.
Gaujoux-Viala, C., Fautrel, B.: Cost effectiveness of therapeutic interventions in ankylosis spondylitis. Pharmacoeconomics 30(12), 1145–1156 (2012)PubMedCrossRef
30.
de Pouvourville, G., Ulmann, P., Nixon, J., Boulenger, S., Glanville, J., Drummond, M.: The diffusion of health economics knowledge in Europe : the EURONHEED (European Network of Health Economics Evaluation Database) project. Pharmacoeconomics 23(2), 113–120 (2005)PubMedCrossRef
31.
Knies, S.: Transparency of transferability: diagnosing international aspects of economic evaluations of health care technologies. Universitaire Pers, Maastricht (2011)
32.
Adapting existing HTAs from one country into other settings. EUnetHTA Adaptation Toolkit: Version 5. EUnetHTA (2011)
33.
Reinhold, T., Brüggenjürgen, B., Schlander, M., Rosenfeld, S., Hessel, F., Willich, S.N.: Economic analysis based on multinational studies: methods for adapting findings to national contexts. J. Publ. Health. 18(4), 327–335 (2005)CrossRef
34.
Nixon, J., Rice, S., Drummond, M., Boulenger, S., Ulmann, P., de Pouvourville, G.: Guidelines for completing the EURONHEED transferability information checklists. Eur. J. Health Econ. 10(2), 157–165 (2008)PubMedCrossRef
35.
Gulácsi, L., Orlewska, E., Péntek, M.: Health economics and health technology assessment in Central and Eastern Europe: a dose of reality. Eur. J. Health Econ. 13(5), 525–531 (2012)PubMedCrossRef
36.
Boncz, I., Nagy, J., Sebestyen, A., Korosi, L.: Financing of health care services in Hungary. Eur. J. Health Econ. 5(3), 252–258 (2004)PubMedCrossRef
37.
Boncz, I., Sebestyen, A.: Financial deficits in the health services of the UK and Hungary. Lancet 368(9539), 917–918 (2006)PubMedCrossRef
Metadaten
Titel
Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries
verfasst von
László Gulácsi
Fanni Rencz
Márta Péntek
Valentin Brodszky
Ruth Lopert
Noémi V. Hevér
Petra Baji
Publikationsdatum
01.05.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe Sonderheft 1/2014
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-014-0591-7

Weitere Artikel der Sonderheft 1/2014

The European Journal of Health Economics 1/2014 Zur Ausgabe

Original Paper

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis

Original Paper

Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists

Original Paper

Statistical and regulatory considerations in assessments of interchangeability of biological drug products

Original Paper

Economic burden of long-term care of rheumatoid arthritis patients in Hungary

Original Paper

Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis

Original Paper

Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary